Shire and the Foundation Fighting Blindness have entered a research agreement to find novel treatments for aurosomal dominant retinitis pigmentosa (adRP).
The rare genetic disease usually first occurs in late childhood or adolescence and is typically followed by the progressive loss of peripheral vision.
As part of the agreement, the Foundation and its research partners will provide Shire with knowledge and scientific background regarding adRP in addition to clinical information that could progress findings.
Albert Seymour, senior VP of global research and non-clinical development at Shire, commented: “This agreement is an example of the creative approaches in early-stage rare disease research and development that we are taking at Shire.
“Both organisations have a strong, shared commitment to unearthing and developing innovative treatments in areas of significant, unmet medical need.”
The Foundation will also provide counsel where necessary concerning pre clinical and clinical development of Shire compounds in the development process.
Shire will in turn compensate the Foundation and makes its own expertise and experience in investigational new drug applications available when needed.
Patricia Zilliox, chief drug development officer at the Foundation Fighting Blindness Clinical Research Institute, added: “Through our agreement with Shire, we are excited to drive research and development and extend our expertise to dedicated partners working to accelerate treatments for those living with retinal diseases.”